Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||IGF2: an endocrine hormone to improve islet transplant survival|
|Citation:||Journal of Endocrinology, 2014; 221(2):R41-R48|
|Amy Hughes, Darling Rojas-Canales, Chris Drogemuller, Nicolas H Voelcker, Shane T Grey and P T H Coates|
|Abstract:||In the week following pancreatic islet transplantation, up to 50% of transplanted islets are lost due to apoptotic cell death triggered by hypoxic and pro-inflammatory cytokine-mediated cell stress. Thus, therapeutic approaches designed to protect islet cells from apoptosis could significantly improve islet transplant success. IGF2 is an anti-apoptotic endocrine protein that inhibits apoptotic cell death through the mitochondrial (intrinsic pathway) or via antagonising activation of pro-inflammatory cytokine signalling (extrinsic pathway), in doing so IGF2 has emerged as a promising therapeutic molecule to improve islet survival in the immediate post-transplant period. The development of novel biomaterials coated with IGF2 is a promising strategy to achieve this. This review examines the mechanisms mediating islet cell apoptosis in the peri- and post-transplant period and aims to identify the utility of IGF2 to promote islet survival and enhance long-term insulin independence rates within the setting of clinical islet transplantation.|
|Keywords:||insulin-like growth factor; apoptosis; islets; cell survival; islet transplantation|
|Rights:||© 2014 Society for Endocrinology|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.